SPIMACO turns to SAR 76.8 mln profit in H1, Q2 at SAR 22.1 mln

08/08/2023 Argaam Exclusive

View other reports

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) reported a net profit of SAR 76.8 million in H1 2023, versus a net loss of SAR 13.3 million in a year earlier period.

Financials (M)

Item	6m 2022	6m 2023	Change‬
Revenues	699.95	940.83	34.4 %
Gross Income	305.89	440.42	44.0 %
Operating Income	2.55	116.20	4462.2 %
Net Income	(13.33)	77.04	678.1 %
Average Shares	120.00	120.00	-
EPS (Riyals)	(0.11)	0.64	678.1 %

Revenue increased by 34.4%, or SAR 240.9 million, to SAR 940.8 million on the back of a beneficial change in the client mix, expansion of sales across the private and government channels, and a rise in sales volume due to high demand for the company's products.

Gross Profit increased by 44% YoY, or SAR 134.5 million, to SAR 440.4 million for H1 2023 as a result of strong growth of 34% YoY in H1 2023 revenue.

Depreciation and amortization expenses decreased by 8.6% to SAR 41.5 million compared to SAR 45.4 million in H1 2022.

SPIMACO’s net profit for Q2 2023 reached SAR 22.1 million, compared to a net loss of SAR 46.65 million in Q2 2022.

Current Quarter Comparison (M)

Compared With The

Item	Q2 2022	Q2 2023	Change‬
Revenues	310.62	408.72	31.6 %
Gross Income	120.18	183.49	52.7 %
Operating Income	(45.26)	33.67	174.4 %
Net Income	(46.65)	22.29	147.8 %
Average Shares	120.00	120.00	-
EPS (Riyals)	(0.39)	0.19	147.8 %

Item	Q1 2023	Q2 2023	Change‬
Revenues	531.77	408.72	(23.1 %)
Gross Income	257.32	183.49	(28.7 %)
Operating Income	83.37	33.67	(59.6 %)
Net Income	54.75	22.29	(59.3 %)
Average Shares	120.00	120.00	-
EPS (Riyals)	0.46	0.19	(59.3 %)

This was spurred by a revenue increase of 31.6% YoY to SAR 408.7 million on the back of strong growth in revenue from selling products as well as services.

Gross profit rose 52.7% YoY to SAR 183.5 million in Q2 2023, primarily due to the revised commercial strategy, which saw a favorable shift in the client mix and an upgrade in the marketable portfolio coupled with tight cost control.

The company also cited lower selling, general, and administrative expenses (SG&As).

On a quarterly basis, net earnings plunged 59.7% from SAR 54.74 million.

Shareholders’ equity, with no minority interest, stood at SAR 1.60 billion as of June 30, 2023, compared to SAR 1.74 billion a year earlier.

Accumulated losses reached SAR 102.1 million as of June 30, 2023, representing 9% of capital.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Net Income	Change	EPS(Riyal)
Q1 2014	405.21	12.1 %	206.72	12.0 %	91.17	44.4 %	0.76
Q2 2014	371.14	7.8 %	193.14	7.8 %	97.72	(14.1 %)	0.81
Q3 2014	266.02	19.3 %	134.45	13.3 %	36.69	7.3 %	0.31
Q4 2014	431.06	12.8 %	261.80	15.8 %	91.29	60.1 %	0.76
2014	1,470.19	12.2 %	794.54	12.1 %	316.85	18.8 %	2.64
Q1 2015	432.20	6.7 %	225.86	9.3 %	99.39	9.0 %	0.83
Q2 2015	435.80	17.4 %	210.95	9.2 %	237.63	143.2 %	1.98
Q3 2015	308.27	15.9 %	131.32	(2.3 %)	29.16	(20.5 %)	0.24
Q4 2015	520.38	20.7 %	266.38	1.7 %	(9.12)	(110.0 %)	(0.08)
2015	1,705.05	16.0 %	848.60	6.8 %	357.05	12.7 %	2.98
Q1 2016	322.20	(25.4 %)	194.26	(14.0 %)	88.91	(10.5 %)	0.74
Q2 2016	339.54	(22.1 %)	183.58	(13.0 %)	39.61	(83.3 %)	0.33
Q3 2016	257.21	(16.6 %)	140.54	7.0 %	4.76	(83.7 %)	0.04
Q4 2016	339.59	(34.7 %)	194.16	(27.1 %)	143.48	1673.8 %	1.20
2016	1,258.55	(26.2 %)	712.54	(16.0 %)	276.76	(22.5 %)	2.31
Q1 2017	393.10	22.0 %	212.58	9.4 %	101.22	13.8 %	0.84
Q2 2017	304.63	(10.3 %)	156.13	(15.0 %)	46.56	17.5 %	0.39
Q3 2017	277.62	7.9 %	128.68	(8.4 %)	(17.03)	(457.9 %)	(0.14)
Q4 2017	410.69	20.9 %	207.07	6.7 %	66.61	(53.6 %)	0.56
2017	1,386.04	10.1 %	704.46	(1.1 %)	197.37	(28.7 %)	1.64
Q1 2018	390.79	(0.6 %)	197.32	(7.2 %)	55.23	(45.4 %)	0.46
Q2 2018	295.62	(3.0 %)	155.28	(0.5 %)	22.67	(51.3 %)	0.19
Q3 2018	224.95	(19.0 %)	137.89	7.2 %	(12.12)	28.8 %	(0.10)
Q4 2018	600.79	46.3 %	127.79	(38.3 %)	19.01	(71.5 %)	0.16
2018	1,503.32	8.5 %	608.52	(13.6 %)	76.58	(61.2 %)	0.64
Q1 2019	444.80	13.8 %	152.43	(22.7 %)	(21.71)	(139.3 %)	(0.18)
Q2 2019	355.03	20.1 %	95.10	(38.8 %)	(186.49)	(922.8 %)	(1.55)
Q3 2019	342.69	52.3 %	170.82	23.9 %	28.11	332.0 %	0.23
Q4 2019	344.32	(42.7 %)	79.28	(38.0 %)	(259.65)	(1466.1 %)	(2.16)
2019	1,486.85	(1.1 %)	497.64	(18.2 %)	(439.74)	(674.2 %)	(3.66)
Q1 2020	475.72	7.0 %	198.73	30.4 %	45.60	310.1 %	0.38
Q2 2020	328.14	(7.6 %)	150.49	58.2 %	24.98	113.4 %	0.21
Q3 2020	372.91	8.8 %	195.71	14.6 %	67.41	139.8 %	0.56
Q4 2020	378.52	9.9 %	145.55	83.6 %	(13.20)	94.9 %	(0.11)
2020	1,555.29	4.6 %	690.48	38.8 %	124.79	128.4 %	1.04
Q1 2021	454.81	(4.4 %)	142.00	(28.5 %)	26.15	(42.7 %)	0.22
Q2 2021	325.96	(0.7 %)	173.50	15.3 %	31.07	24.4 %	0.26
Q3 2021	311.36	(16.5 %)	145.71	(25.5 %)	7.40	(89.0 %)	0.06
Q4 2021	367.67	(2.9 %)	159.50	9.6 %	(38.15)	(189.1 %)	(0.32)
2021	1,459.78	(6.1 %)	620.71	(10.1 %)	26.45	(78.8 %)	0.22
Q1 2022	389.33	(14.4 %)	185.71	30.8 %	33.33	27.5 %	0.28
Q2 2022	310.62	(4.7 %)	120.18	(30.7 %)	(46.65)	(250.2 %)	(0.39)
Q3 2022	357.02	14.7 %	123.19	(15.5 %)	(45.05)	(709.1 %)	(0.38)
Q4 2022	364.83	(0.8 %)	137.92	(13.5 %)	(106.76)	(179.8 %)	(0.89)
2022	1,421.81	(2.6 %)	567.00	(8.7 %)	(165.14)	(724.2 %)	(1.38)
Q1 2023	531.77	36.6 %	257.32	38.6 %	54.75	64.3 %	0.46
Q2 2023	408.72	31.6 %	183.49	52.7 %	22.29	147.8 %	0.19

Period	Revenues	Change	Gross Income	Change	Net Income	Change	EPS(Riyal)
2013	1,310.50	10.8 %	708.52	14.5 %	266.82	14.7 %	2.22
2014	1,470.19	12.2 %	794.54	12.1 %	316.85	18.8 %	2.64
2015	1,705.05	16.0 %	848.60	6.8 %	357.05	12.7 %	2.98
2016	1,258.55	(26.2 %)	712.54	(16.0 %)	276.76	(22.5 %)	2.31
2017	1,386.04	10.1 %	704.46	(1.1 %)	197.37	(28.7 %)	1.64
2018	1,503.32	8.5 %	608.52	(13.6 %)	76.58	(61.2 %)	0.64
2019	1,486.85	(1.1 %)	497.64	(18.2 %)	(439.74)	(674.2 %)	(3.66)
2020	1,555.29	4.6 %	690.48	38.8 %	124.79	128.4 %	1.04
2021	1,459.78	(6.1 %)	620.71	(10.1 %)	26.45	(78.8 %)	0.22
2022	1,421.81	(2.6 %)	567.00	(8.7 %)	(165.14)	(724.2 %)	(1.38)

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	53.95 %	17.92 %	21.86 %
Q2 2014	53.91 %	17.74 %	20.28 %
Q3 2014	53.39 %	16.79 %	19.84 %
Q4 2014	54.03 %	18.15 %	21.50 %
2014	54.04 %	18.15 %	21.55 %
Q1 2015	54.34 %	18.90 %	21.67 %
Q2 2015	53.23 %	18.31 %	20.04 %
Q3 2015	51.63 %	17.40 %	19.05 %
Q4 2015	49.19 %	17.17 %	19.11 %
2015	49.77 %	16.85 %	19.02 %
Q1 2016	50.60 %	15.90 %	18.80 %
Q2 2016	52.04 %	15.52 %	16.88 %
Q3 2016	54.52 %	15.09 %	15.79 %
Q4 2016	56.62 %	10.25 %	5.68 %
2016	56.62 %	10.25 %	5.68 %
Q1 2017	54.97 %	9.67 %	3.99 %
Q2 2017	54.34 %	11.85 %	4.64 %
Q3 2017	52.59 %	11.94 %	2.91 %
Q4 2017	50.83 %	14.96 %	9.94 %
2017	50.83 %	14.96 %	9.94 %
Q1 2018	49.81 %	16.45 %	9.97 %
Q2 2018	50.07 %	14.49 %	8.30 %
Q3 2018	52.76 %	15.07 %	9.00 %
Q4 2018	40.89 %	5.68 %	5.61 %
2018	40.48 %	4.92 %	5.09 %
Q1 2019	36.61 %	2.64 %	0.50 %
Q2 2019	31.57 %	(2.89 %)	(5.68 %)
Q3 2019	31.33 %	0.66 %	(2.99 %)
Q4 2019	33.47 %	1.46 %	(13.51 %)
2019	33.47 %	1.46 %	(13.51 %)
Q1 2020	35.84 %	4.49 %	(8.80 %)
Q2 2020	40.20 %	10.74 %	(2.08 %)
Q3 2020	41.04 %	11.13 %	0.55 %
Q4 2020	44.40 %	14.83 %	8.02 %
2020	44.40 %	14.83 %	8.02 %
Q1 2021	41.30 %	12.43 %	6.86 %
Q2 2021	42.86 %	13.79 %	7.27 %
Q3 2021	41.26 %	10.94 %	3.50 %
Q4 2021	42.52 %	9.78 %	1.81 %
2021	42.52 %	9.78 %	1.81 %
Q1 2022	47.65 %	12.35 %	2.41 %
Q2 2022	44.31 %	6.97 %	(3.20 %)
Q3 2022	41.31 %	2.84 %	(6.78 %)
Q4 2022	39.88 %	(1.35 %)	(11.61 %)
2022	39.88 %	(1.35 %)	(11.61 %)
Q1 2023	40.83 %	0.94 %	(9.19 %)
Q2 2023	42.22 %	5.64 %	(4.50 %)

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2013	54.06 %	18.16 %	20.36 %
2014	54.04 %	18.15 %	21.55 %
2015	49.77 %	16.85 %	19.02 %
2016	56.62 %	10.25 %	5.68 %
2017	50.83 %	14.96 %	9.94 %
2018	40.48 %	4.92 %	5.09 %
2019	33.47 %	1.46 %	(13.51 %)
2020	44.40 %	14.83 %	8.02 %
2021	42.52 %	9.78 %	1.81 %
2022	39.88 %	(1.35 %)	(11.61 %)

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	51.02 %	20.19 %	22.50 %
Q2 2014	52.04 %	13.80 %	26.33 %
Q3 2014	50.54 %	13.97 %	13.79 %
Q4 2014	60.73 %	22.54 %	21.18 %
Q1 2015	52.26 %	22.70 %	23.00 %
Q2 2015	48.40 %	12.42 %	19.81 %
Q3 2015	42.60 %	9.85 %	9.46 %
Q4 2015	51.19 %	20.88 %	21.02 %
Q1 2016	60.29 %	18.36 %	22.80 %
Q2 2016	54.07 %	9.77 %	11.67 %
Q3 2016	54.64 %	6.30 %	1.85 %
Q4 2016	57.18 %	6.04 %	(13.65 %)
Q1 2017	54.08 %	14.94 %	14.01 %
Q2 2017	51.25 %	19.02 %	15.29 %
Q3 2017	46.35 %	7.17 %	(6.13 %)
Q4 2017	50.42 %	17.25 %	12.96 %
Q1 2018	50.49 %	20.19 %	14.13 %
Q2 2018	52.53 %	9.98 %	7.67 %
Q3 2018	61.30 %	8.88 %	(5.39 %)
Q4 2018	21.27 %	(7.08 %)	3.16 %
Q1 2019	34.27 %	7.75 %	(4.88 %)
Q2 2019	26.79 %	(16.60 %)	(21.86 %)
Q3 2019	49.85 %	22.90 %	8.20 %
Q4 2019	23.03 %	(9.36 %)	(37.65 %)
Q1 2020	41.77 %	16.99 %	9.59 %
Q2 2020	45.86 %	10.09 %	7.61 %
Q3 2020	52.48 %	23.49 %	18.08 %
Q4 2020	38.45 %	7.68 %	(3.49 %)
Q1 2021	31.22 %	9.00 %	5.75 %
Q2 2021	53.23 %	16.47 %	9.53 %
Q3 2021	46.80 %	11.95 %	2.38 %
Q4 2021	43.38 %	2.98 %	(10.38 %)
Q1 2022	47.70 %	18.06 %	8.56 %
Q2 2022	38.69 %	(7.20 %)	(15.02 %)
Q3 2022	34.51 %	(5.17 %)	(12.62 %)
Q4 2022	37.80 %	(13.36 %)	(29.26 %)
Q1 2023	48.39 %	19.62 %	10.29 %
Q2 2023	44.89 %	13.87 %	5.45 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2014	120.00	2.47	2.47	32.96
Q2 2014	120.00	2.33	2.33	33.21
Q3 2014	120.00	2.35	2.35	35.74
Q4 2014	120.00	2.64	2.64	28.75
Q1 2015	120.00	2.71	2.71	27.84
Q2 2015	120.00	3.87	2.61	28.72
Q3 2015	120.00	3.81	2.55	24.87
Q4 2015	120.00	2.98	2.70	22.17
Q1 2016	120.00	2.89	2.49	20.84
Q2 2016	120.00	1.24	2.10	20.49
Q3 2016	120.00	1.03	1.89	20.40
Q4 2016	120.00	2.31	0.60	22.59
Q1 2017	120.00	2.41	0.44	23.27
Q2 2017	120.00	2.47	0.50	21.52
Q3 2017	120.00	2.29	0.32	22.01
Q4 2017	120.00	1.64	1.15	22.78
Q1 2018	120.00	1.26	1.15	25.04
Q2 2018	120.00	1.06	0.95	25.74
Q3 2018	120.00	1.10	0.99	24.32
Q4 2018	120.00	0.71	0.71	21.17
Q1 2019	120.00	0.07	0.07	22.80
Q2 2019	120.00	(1.68)	(0.77)	19.63
Q3 2019	120.00	(1.34)	(0.43)	18.36
Q4 2019	120.00	(3.66)	(1.67)	16.20
Q1 2020	120.00	(3.10)	(1.11)	14.14
Q2 2020	120.00	(1.34)	(0.26)	14.67
Q3 2020	120.00	(1.01)	0.07	15.63
Q4 2020	120.00	1.04	1.04	15.96
Q1 2021	120.00	0.88	0.88	16.29
Q2 2021	120.00	0.93	0.93	15.54
Q3 2021	120.00	0.43	0.43	15.53
Q4 2021	120.00	0.22	0.22	15.31
Q1 2022	120.00	0.28	0.28	15.53
Q2 2022	120.00	(0.37)	(0.37)	14.54
Q3 2022	120.00	(0.80)	(0.80)	14.13
Q4 2022	120.00	(1.38)	(1.38)	12.83
Q1 2023	120.00	(1.20)	(1.20)	13.29
Q2 2023	120.00	(0.62)	(0.62)	13.36

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2013	120.00	2.22	2.22	32.18
2014	120.00	2.64	2.64	28.75
2015	120.00	2.98	2.70	22.17
2016	120.00	2.31	0.60	22.59
2017	120.00	1.64	1.15	22.78
2018	120.00	0.64	0.64	21.17
2019	120.00	(3.66)	(1.67)	16.20
2020	120.00	1.04	1.04	15.96
2021	120.00	0.22	0.22	15.31
2022	120.00	(1.38)	(1.38)	12.83

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2014	19.07	19.07	1.43
Q2 2014	19.29	19.29	1.36
Q3 2014	21.41	21.41	1.41
Q4 2014	12.89	12.89	1.18
Q1 2015	14.78	14.78	1.44
Q2 2015	11.59	17.18	1.56
Q3 2015	9.46	14.14	1.45
Q4 2015	11.16	12.29	1.50
Q1 2016	11.15	12.96	1.55
Q2 2016	29.96	17.69	1.81
Q3 2016	30.18	16.49	1.53
Q4 2016	17.72	68.63	1.81
Q1 2017	15.03	81.82	1.56
Q2 2017	14.32	70.59	1.64
Q3 2017	14.43	More than 100	1.50
Q4 2017	18.25	26.14	1.32
Q1 2018	24.34	26.70	1.23
Q2 2018	30.03	33.56	1.24
Q3 2018	28.37	31.57	1.29
Q4 2018	41.61	41.61	1.39
Q1 2019	More than 100	More than 100	1.21
Q2 2019	NEG	NEG	1.35
Q3 2019	NEG	NEG	1.43
Q4 2019	NEG	NEG	1.68
Q1 2020	NEG	NEG	1.91
Q2 2020	NEG	NEG	1.98
Q3 2020	NEG	More than 100	2.34
Q4 2020	37.70	37.70	2.46
Q1 2021	46.94	46.94	2.53
Q2 2021	62.14	62.14	3.71
Q3 2021	More than 100	More than 100	3.00
Q4 2021	More than 100	More than 100	2.57
Q1 2022	More than 100	More than 100	2.40
Q2 2022	NEG	NEG	1.79
Q3 2022	NEG	NEG	1.85
Q4 2022	NEG	NEG	1.70
Q1 2023	NEG	NEG	1.79
Q2 2023	NEG	NEG	2.85

Period	P/E	Adjusted P/E	Price/book
2013	19.11	19.11	1.32
2014	12.89	12.89	1.18
2015	11.16	12.29	1.50
2016	17.72	68.63	1.81
2017	18.25	26.14	1.32
2018	46.07	46.07	1.39
2019	NEG	NEG	1.68
2020	37.70	37.70	2.46
2021	More than 100	More than 100	2.57
2022	NEG	NEG	1.70

Business Segments (Million)

Compared With The

Period	Pharmaceutical Manufacturing	healthy services and other	Trading & Distribution Services	Contract manufacturing arrangements	Medical & Pharmaceutical production segment	Investment activity	Eliminations	Other
Q1 2014	-	-	-	-	405.21	-	-	-
Q2 2014	-	-	-	-	374.14	-	-	-
Q3 2014	-	-	-	-	266.02	-	-	-
Q4 2014	-	-	-	-	427.82	-	-	-
Q1 2015	-	-	-	-	432.29	14.84	-	-
Q2 2015	-	-	-	-	436.99	195.93	-	-
Q3 2015	-	-	-	-	308.38	9.55	-	-
Q4 2015	-	-	-	-	529.24	-	-	-
Q1 2016	-	-	-	-	513.97	25.27	-	-
Q2 2016	-	-	-	-	494.92	9.41	-	-
Q3 2016	-	-	-	-	100.39	6.23	-	-
Q4 2016	-	-	-	-	401.35	247.84	-	-
Q1 2017	-	-	-	-	446.00	50.90	(51.45)	-
Q2 2017	-	-	-	-	350.01	1.39	(43.30)	-
Q3 2017	-	-	-	-	317.29	4.01	(36.78)	-
Q4 2017	-	-	-	-	486.15	-	(54.74)	-
Q1 2018	-	-	-	-	450.19	7.00	(57.49)	-
Q3 2018	172.41	34.26	1.75	16.54	-	-	-	-
Q1 2019	419.76	22.19	2.03	0.82	-	-	-	-
Q2 2019	334.00	19.00	0.91	1.12	-	-	-	-
Q3 2019	313.52	20.79	7.10	1.29	-	-	-	-
Q1 2020	449.65	22.39	1.55	2.13	-	-	-	-
Q2 2020	295.05	27.32	5.12	0.65	-	-	-	-
Q3 2020	348.38	22.04	0.75	1.74	-	-	-	-
Q4 2020	349.04	20.89	6.83	1.76	-	-	-	-
Q1 2021	407.34	20.92	26.29	0.25	-	-	-	-
Q2 2021	314.20	27.04	-	2.98	-	-	-	-
Q3 2021	276.02	28.96	0.06	6.32	-	-	-	-
Q4 2021	336.97	26.95	-	6.42	-	-	-	-
Q1 2022	354.53	30.22	4.44	0.14	-	-	-	-
Q2 2022	244.52	27.85	38.40	-	-	-	-	-
Q3 2022	298.78	33.20	25.04	-	-	-	-	-
Q4 2022	(505.09)	38.04	831.88	-	-	-	-	-
Q1 2023	431.67	37.35	62.75	-	-	-	-	-
Q2 2023	288.00	38.90	82.85	-	-	-	-	-

Period	Pharmaceutical Manufacturing	healthy services and other	Trading & Distribution Services	Contract manufacturing arrangements	Medical & Pharmaceutical production segment	Investment activity	Eliminations	Other
2013	-	-	-	-	1,310.50	-	-	-
2014	-	-	-	-	1,470.19	-	-	-
2015	-	-	-	-	1,706.80	115.14	-	-
2016	-	-	-	-	1,510.63	288.74	(244.41)	-
2017	-	-	-	-	1,599.45	61.92	(186.28)	-
2018	1,414.72	78.37	5.02	5.22	-	-	-	-
2019	1,397.28	77.87	5.93	5.76	-	-	-	-
2020	1,442.13	92.64	14.25	6.27	-	-	-	-
2021	1,334.53	103.88	5.41	15.97	-	-	-	-
2022	392.74	129.31	899.76	-	-	-	-	4.72

Analysts Estimates (Million)

Item	Q2 2023 (e)	Q2 2023 (a)	Change‬
Average	(2.67)	22.29	935.95 %

Estimates vs Actual (Million)

Item	Q2 2023 (e)	Q2 2023 (a)	Change
Hermes	21.00	22.29	6.2 %
Al Rajhi Capital	(19.00)	22.29	217.3 %
HSBC	(10.00)	22.29	322.9 %

Financial Ratios

	Current
Market Cap (M Riyal)	3,474.00
Enterprise Value (EV) (M)	4,555.48
Shares Outstanding ((M))	120.00
EPS ( Riyal) (TTM)	(0.27)
Book Value (BV) ( Riyal)	12.89
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	Neg
P/E (TTM)	NEG
Price/book	2.25
Return on Average Assets (%) (TTM)	(0.76 )
Return on Average Equity (%) (TTM)	(2.09 )

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

SPIMACO turns to SAR 76.8 mln profit in H1, Q2 at SAR 22.1 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2023 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

SPIMACO turns to SAR 76.8 mln profit in H1, Q2 at SAR 22.1 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2023

Revenue by Business Segment (Latest) 2023 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)